RU2378260C2 - 4-аминохиназолиновые антагонисты селективных натриевых и кальциевых ионных каналов - Google Patents

4-аминохиназолиновые антагонисты селективных натриевых и кальциевых ионных каналов Download PDF

Info

Publication number
RU2378260C2
RU2378260C2 RU2005130486/04A RU2005130486A RU2378260C2 RU 2378260 C2 RU2378260 C2 RU 2378260C2 RU 2005130486/04 A RU2005130486/04 A RU 2005130486/04A RU 2005130486 A RU2005130486 A RU 2005130486A RU 2378260 C2 RU2378260 C2 RU 2378260C2
Authority
RU
Russia
Prior art keywords
och
optionally substituted
ring
compounds
taken together
Prior art date
Application number
RU2005130486/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2005130486A (ru
Inventor
Хесус Э. ГОНСАЛЕС III (US)
Хесус Э. ГОНСАЛЕС III
Дин Митчелл УИЛСОН (US)
Дин Митчелл УИЛСОН
Андреас Питер ТЕРМИН (US)
Андреас Питер ТЕРМИН
Петер Дидерик Ян ГРОТЕНХЕЙС (US)
Петер Дидерик Ян ГРОТЕНХЕЙС
Юлянь ЧЖАН (US)
Юлянь ЧЖАН
Бенджамин Джон ПЕЦОЛДТ (US)
Бенджамин Джон ПЕЦОЛДТ
Лев Тайлер Деви ФЭННИНГ (US)
Лев Тайлер Деви ФЭННИНГ
Тимоти Доналд НЬЮБЕРТ (US)
Тимоти Доналд НЬЮБЕРТ
Роджер Д. ТУНГ (US)
Роджер Д. Тунг
Эстер МАРТИНБОРО (US)
Эстер МАРТИНБОРО
Николе ЦИММЕРМАНН (US)
Николе ЦИММЕРМАНН
Original Assignee
Вертекс Фармасьютикалз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вертекс Фармасьютикалз Инкорпорейтед filed Critical Вертекс Фармасьютикалз Инкорпорейтед
Publication of RU2005130486A publication Critical patent/RU2005130486A/ru
Application granted granted Critical
Publication of RU2378260C2 publication Critical patent/RU2378260C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2005130486/04A 2003-03-03 2004-03-03 4-аминохиназолиновые антагонисты селективных натриевых и кальциевых ионных каналов RU2378260C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45145803P 2003-03-03 2003-03-03
US60/451,458 2003-03-03
US46379703P 2003-04-18 2003-04-18
US60/463,797 2003-04-18

Publications (2)

Publication Number Publication Date
RU2005130486A RU2005130486A (ru) 2006-05-10
RU2378260C2 true RU2378260C2 (ru) 2010-01-10

Family

ID=32965550

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005130486/04A RU2378260C2 (ru) 2003-03-03 2004-03-03 4-аминохиназолиновые антагонисты селективных натриевых и кальциевых ионных каналов

Country Status (20)

Country Link
US (2) US7678802B2 (enExample)
EP (1) EP1608632B1 (enExample)
JP (1) JP5247027B2 (enExample)
KR (1) KR20050108379A (enExample)
AR (1) AR044502A1 (enExample)
AT (1) ATE453629T1 (enExample)
AU (1) AU2004217891B2 (enExample)
BR (1) BRPI0408026A (enExample)
CA (1) CA2517844A1 (enExample)
CL (1) CL2004000409A1 (enExample)
DE (1) DE602004024873D1 (enExample)
ES (1) ES2338553T3 (enExample)
IL (1) IL170636A (enExample)
NO (1) NO20054546L (enExample)
NZ (1) NZ542664A (enExample)
PE (1) PE20041059A1 (enExample)
RU (1) RU2378260C2 (enExample)
TW (1) TW200426147A (enExample)
UY (1) UY28215A1 (enExample)
WO (1) WO2004078733A1 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713983B2 (en) * 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
EP1635846A4 (en) * 2003-06-20 2009-01-28 Coley Pharm Gmbh SMALL MOLECULAR TLR (TOLL-LIKE RECEPTOR) ANTAGONISTS
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
TWI344364B (en) * 2003-11-10 2011-07-01 Synta Pharmaceuticals Corp Fused heterocyclic compounds
EP1784393B1 (en) * 2004-09-02 2009-07-01 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
ZA200704972B (en) * 2004-12-17 2008-09-25 Vertex Pharma Processes for producing 4-aminoquinazolines
US8252806B2 (en) 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
JP5112297B2 (ja) * 2005-05-20 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なキノリン誘導体
FR2891829A1 (fr) * 2005-10-12 2007-04-13 Sanofi Aventis Sa Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
ES2377988T3 (es) 2005-11-14 2012-04-03 Vertex Pharmaceuticals, Inc. Quinazolinas útiles como moduladores de canales iónicos controlados por voltaje
KR20080070749A (ko) 2005-11-23 2008-07-30 페인셉터 파마 코포레이션 개폐 이온 통로를 조절하기 위한 조성물 및 방법
JP2009520700A (ja) * 2005-12-21 2009-05-28 ペインセプター ファーマ コーポレーション 依存性イオンチャネルを調節するための組成物および方法
WO2007115410A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
EP2024333A2 (en) 2006-04-26 2009-02-18 Cancer Research Technology Limited Amino-ethyl-amino-aryl (aeaa) compounds and their use
MX2008015908A (es) 2006-06-12 2009-01-28 Vertex Pharma Tienopirimidinas utiles como moduladores de canales de iones.
CA2661307C (en) * 2006-08-22 2016-07-19 Technion Research And Development Foundation Ltd. Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr)
AU2007304195A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
CN101547922B (zh) 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
EP2099458A4 (en) * 2006-12-01 2011-05-11 Harvard College COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR PRESENTATION AND THERAPY
CN101778825A (zh) * 2007-03-22 2010-07-14 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的n-杂环类化合物
US8759348B2 (en) * 2007-05-17 2014-06-24 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
US20090209536A1 (en) * 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009000085A1 (en) * 2007-06-27 2008-12-31 Painceptor Pharma Corporation Quinoline and quinazoline derivatives useful as modulators of gated ion channels
US8324226B2 (en) * 2007-10-24 2012-12-04 Cancer Research Technology Limited Therapeutic oxy-phenyl-aryl compounds and their use
JP5362839B2 (ja) * 2008-11-14 2013-12-11 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ３受容体アンタゴニストとしてのキナゾリン誘導体
WO2010135568A1 (en) * 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and their use to treat cancer
CA2763099A1 (en) * 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
WO2010151595A1 (en) * 2009-06-26 2010-12-29 Schering Corporation Pyrrolo-benzo-1,4-diazines useful as sodium channel blockers
US20110053916A1 (en) 2009-08-14 2011-03-03 Vertex Pharmaceuticals Incorporated Pyrimidine compounds as tuberculosis inhibitors
EP3575288B1 (en) 2009-09-03 2021-10-27 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9045435B2 (en) 2010-10-05 2015-06-02 Purdue Pharma, L.P. Quinazoline compounds as sodium channel blockers
JP5937102B2 (ja) * 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
US9458131B2 (en) 2011-11-08 2016-10-04 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
WO2013143319A1 (zh) * 2012-03-26 2013-10-03 中国科学院福建物质结构研究所 喹唑啉衍生物及其用途
EP2865671B1 (en) * 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
WO2014074517A1 (en) * 2012-11-08 2014-05-15 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2015066584A1 (en) * 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
JP2016516691A (ja) * 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのイソキノリン
CN105492439B (zh) 2013-06-21 2019-11-22 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的取代的双环化合物
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN103755649A (zh) * 2013-12-31 2014-04-30 李增 一种喹唑啉衍生物及其作为血管生成抑制剂的应用
AU2015223049B2 (en) * 2014-02-27 2019-03-21 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
US10035780B2 (en) 2014-04-23 2018-07-31 Technion Research & Development Foundation Ltd. Quinazoline scaffold based compounds, pharmaceutical compositions and methods of use thereof
WO2016061280A1 (en) * 2014-10-14 2016-04-21 La Jolla Institute Of Allergy & Immunology Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
HK1246273B (en) 2014-12-01 2019-12-06 恒翼生物医药(上海)股份有限公司 Substituted pyridines as bromodomain inhibitors
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016090299A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Novel quinazolines as biogenic amine transport modulators
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
US10323018B2 (en) * 2015-01-20 2019-06-18 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
WO2017075222A1 (en) * 2015-10-30 2017-05-04 Lieber Institute For Brain Development Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
KR102327053B1 (ko) * 2017-03-16 2021-11-17 기초과학연구원 퀴나졸린, 퀴놀린 유도체 및 egfr 키나제 억제제로서의 용도
WO2018204176A1 (en) 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
CA3071534A1 (en) * 2017-08-02 2019-02-07 Northwestern University Substituted fused pyrimidine compounds and uses thereof
WO2019152724A1 (en) * 2018-02-02 2019-08-08 Prozyme, Inc. Methods and kits for using blocked 2-aa for glycan analysis
WO2020021064A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
SG11202105685TA (en) * 2019-01-03 2021-06-29 Univ Pittsburgh Commonwealth Sys Higher Education Methods and materials for increasing transcription factor eb polypeptide levels
JP7478251B2 (ja) * 2019-12-14 2024-05-02 シャンハイ イースト ホスピタル（イースト ホスピタル，トンジ ユニバーシティ スクール オブ メディシン） イオンチャネルアンタゴニスト／遮断剤およびその用途
US20240425493A1 (en) * 2023-06-13 2024-12-26 The Trustees Of Indiana University Small molecule antiviral drug treatment for human papillomavirus infections

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340260A (en) * 1962-12-03 1967-09-05 Ciba Geigy Corp 4-amino-pyrimidines
US3637693A (en) * 1968-07-12 1972-01-25 Du Pont Hydroxyarylquinazolines and their use as uv-absorbers
EP0655465A1 (de) * 1993-11-25 1995-05-31 BASF Aktiengesellschaft Verfahren zum Beseitigen restflüchtiger Anteile aus Polyacrylatschmelzen
JP2000229950A (ja) * 1999-02-12 2000-08-22 Agency Of Ind Science & Technol キナゾリン誘導体又はその塩の製造方法
EP1231211A1 (en) * 1999-11-18 2002-08-14 Vita-Invest, S.A. Thiazolidinedione derivatives as antidiabetic agents
RU2198879C2 (ru) * 1996-09-25 2003-02-20 Зенека Лимитед Производные хиназолина, способы их получения, содержащие их фармацевтические композиции, способ достижения антиангиогенного и/или эффекта снижения проницаемости кровеносных сосудов у теплокровного животного

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE119051C (enExample)
NL292083A (enExample) * 1962-09-18
GB1199768A (en) * 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
US3705898A (en) * 1970-01-26 1972-12-12 Morton Norwich Products Inc Certain 4 - amino - 2-(5-nitro-2-thienyl) quinazolines and the intermediate 4 - chloro-(5 - nitro-2-thienyl)quinazolines therefor
DE2121031A1 (en) * 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
US3819628A (en) * 1972-07-31 1974-06-25 Sandoz Ag 2-phenyl-4-substituted amino-quinazolines and nitrates thereof
CH612432A5 (enExample) * 1975-05-12 1979-07-31 Sandoz Ag
US4377582A (en) * 1979-12-19 1983-03-22 A. H. Robins Company, Inc. 2-Phenyl-4-[cis-2,5-dimethyl-4-(2-pyridinyl)-1-piperazinyl]quinazoline
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
JPS56120768A (en) * 1980-01-31 1981-09-22 Ciba Geigy Ag Color developing quinazoline compound
JPS58172379A (ja) * 1982-04-02 1983-10-11 Showa Denko Kk 新規なキナゾリン誘導体
KR100297623B1 (ko) * 1993-06-17 2001-11-14 오츠까 요시미쯔 포스폰산디에스테르유도체
JPH083144A (ja) 1994-06-21 1996-01-09 Chugai Pharmaceut Co Ltd キナゾリン及びキノリン誘導体
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
WO1998014431A1 (en) * 1996-10-01 1998-04-09 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
FR2751656B1 (fr) * 1996-07-24 1998-10-16 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
BR9714394A (pt) 1996-12-13 2000-05-16 Lilly Co Eli Inibidores da atividade enzimática de psa
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2001068452A (ja) * 1999-08-26 2001-03-16 Matsushita Electric Ind Co Ltd 回路パターン形成済シリコン基板のエッチング装置およびエッチング方法
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
CA2418656C (en) 2000-08-10 2011-02-01 Mitsubishi Pharma Corporation Proline derivatives and use thereof as drugs
PL359920A1 (en) 2000-09-20 2004-09-06 Merck Patent Gmbh 4-amino-quinazolines
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
ES2305744T3 (es) * 2003-03-12 2008-11-01 Millennium Pharmaceuticals, Inc. Derivados de quinazolina como inhibidores e tgf-beta.
TWI289217B (en) * 2004-07-16 2007-11-01 Hon Hai Prec Ind Co Ltd Light guide plate
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) * 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US8283354B2 (en) * 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
ZA200704972B (en) * 2004-12-17 2008-09-25 Vertex Pharma Processes for producing 4-aminoquinazolines
ES2377988T3 (es) 2005-11-14 2012-04-03 Vertex Pharmaceuticals, Inc. Quinazolinas útiles como moduladores de canales iónicos controlados por voltaje

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340260A (en) * 1962-12-03 1967-09-05 Ciba Geigy Corp 4-amino-pyrimidines
US3637693A (en) * 1968-07-12 1972-01-25 Du Pont Hydroxyarylquinazolines and their use as uv-absorbers
EP0655465A1 (de) * 1993-11-25 1995-05-31 BASF Aktiengesellschaft Verfahren zum Beseitigen restflüchtiger Anteile aus Polyacrylatschmelzen
RU2198879C2 (ru) * 1996-09-25 2003-02-20 Зенека Лимитед Производные хиназолина, способы их получения, содержащие их фармацевтические композиции, способ достижения антиангиогенного и/или эффекта снижения проницаемости кровеносных сосудов у теплокровного животного
JP2000229950A (ja) * 1999-02-12 2000-08-22 Agency Of Ind Science & Technol キナゾリン誘導体又はその塩の製造方法
EP1231211A1 (en) * 1999-11-18 2002-08-14 Vita-Invest, S.A. Thiazolidinedione derivatives as antidiabetic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARDELLINI M. et al.: "Derivati della imidazo[1,2-c]chinazolina ad azione inibitoria dell'aggregazione delle piastrine", I1 Farmaco Edizione Scientifica, 1975, vol.30, №7, pp.536-543. *

Also Published As

Publication number Publication date
US20040248890A1 (en) 2004-12-09
JP5247027B2 (ja) 2013-07-24
IL170636A (en) 2012-08-30
WO2004078733A1 (en) 2004-09-16
AU2004217891A1 (en) 2004-09-16
BRPI0408026A (pt) 2006-02-07
PE20041059A1 (es) 2005-02-07
CL2004000409A1 (es) 2005-01-07
EP1608632B1 (en) 2009-12-30
EP1608632A1 (en) 2005-12-28
JP2006522119A (ja) 2006-09-28
AR044502A1 (es) 2005-09-14
NO20054546D0 (no) 2005-10-03
HK1088314A1 (en) 2006-11-03
UY28215A1 (es) 2004-09-30
CA2517844A1 (en) 2004-09-16
AU2004217891B2 (en) 2011-06-23
NO20054546L (no) 2005-11-25
RU2005130486A (ru) 2006-05-10
US20110021495A1 (en) 2011-01-27
KR20050108379A (ko) 2005-11-16
US7678802B2 (en) 2010-03-16
ATE453629T1 (de) 2010-01-15
DE602004024873D1 (de) 2010-02-11
ES2338553T3 (es) 2010-05-10
US8343980B2 (en) 2013-01-01
TW200426147A (en) 2004-12-01
NZ542664A (en) 2009-03-31

Similar Documents

Publication Publication Date Title
RU2378260C2 (ru) 4-аминохиназолиновые антагонисты селективных натриевых и кальциевых ионных каналов
EP1663994B1 (en) Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels
US8153642B2 (en) Quinazolines useful as modulators of ion channels
US8324220B2 (en) Pyrimidines useful as modulators of voltage-gated ion channels
EP2327701A1 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
ES2327945T3 (es) Quinazolinas utiles como moduladores de los canales ionicos.
JP2016512840A (ja) カルボキサミド誘導体及びその使用
ZA200601942B (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US20100249100A1 (en) Quinazolines useful as modulators of ion channels
CN1784391B (zh) 可用作离子通道调控剂的喹唑啉
AU2011250764A1 (en) Condensed Pyrimidine Compounds As Inhibitors Of Voltage-Gated Ion Channels
HK1088314B (en) Quinazolines useful as modulators of ion channels

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130304